Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intranasal immunization against influenza.

Reinhard Glück1

  • 1Berna Biotech Ltd., Rehhagstrasse 79, CH-3018 Bern, Switzerland. marlyse.guidolin@bernabiotech.com

Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine
|August 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine.

Vaccine·2009
Same author

New perspectives for hepatitis B vaccines and immunization.

Vaccine·2009
Same author

Rapid emergence of a viral resistant mutant in WHV chronically infected woodchucks treated with lamivudine and a pre-S/S CHO-derived hepatitis B virus vaccine.

Vaccine·2007
Same author

Adjuvant and antigen delivery properties of virosomes.

Current drug delivery·2005
Same author

A pre-S/S CHO-derived hepatitis B virus vaccine protects woodchucks from WHV productive infection.

Vaccine·2005
Same author

Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch.

Vaccine·2004

Nasalflu, a new intranasal influenza vaccine, utilizes virosome technology to stimulate robust B- and T-cell immunity. This innovative subunit vaccine offers a promising alternative for influenza prevention.

Area of Science:

  • Vaccinology
  • Immunology
  • Virology

Background:

  • Influenza remains a significant global health concern, necessitating effective vaccination strategies.
  • Subunit vaccines offer a favorable safety profile compared to traditional whole-virus vaccines.
  • Virosome technology represents an advanced delivery system for vaccine antigens.

Purpose of the Study:

  • To introduce Nasalflu, a novel intranasal subunit influenza vaccine.
  • To highlight the underlying virosome technology and its potential for inducing cellular and humoral immunity.
  • To position Nasalflu within the context of existing virosomal vaccines.

Main Methods:

  • Administration of Nasalflu via an intranasal spray device.
  • Leveraging the virosome as a carrier system for antigen delivery.

Related Experiment Videos

  • Exploiting the capacity of virosomes to elicit both B-cell and T-cell immune responses.

    • Main Results:

    • Nasalflu is a novel influenza subunit vaccine administered intranasally.
    • The vaccine is based on the established virosomal concept, previously used in licensed vaccines.
    • Virosomes function as antigen delivery systems, capable of inducing both B- and T-cell immunity.

    Conclusions:

    • Nasalflu represents a novel approach to influenza vaccination using intranasal delivery.
    • The virosomal platform is validated by its use in existing vaccines for Hepatitis A and influenza.
    • The technology facilitates antigen presentation to induce comprehensive immune responses, including T-cell immunity.